Peptide vaccines prevent tumor growth by activating T cells that respond to native tumor antigens
Open Access
- 9 March 2010
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 107 (10), 4652-4657
- https://doi.org/10.1073/pnas.0914879107
Abstract
Peptide vaccines enhance the response of T cells toward tumor antigens and represent a strategy to augment antigen-independent immunotherapies of cancer. However, peptide vaccines that include native tumor antigens rarely prevent tumor growth. We have assembled a set of peptide variants for a mouse-colon tumor model to determine how to improve T-cell responses. These peptides have similar affinity for MHC molecules, but differ in the affinity of the peptide-MHC/T-cell receptor interaction with a tumor-specific T-cell clone. We systematically demonstrated that effective antitumor responses are generated after vaccination with variant peptides that stimulate the largest proportion of endogenous T cells specific for the native tumor antigen. Importantly, we found some variant peptides that strongly stimulated a specific T-cell clone in vitro, but elicited fewer tumor-specific T cells in vivo, and were not protective. The T cells expanded by the effective vaccines responded to the wild-type antigen by making cytokines and killing target cells, whereas most of the T cells expanded by the ineffective vaccines only responded to the peptide variants. We conclude that peptide-variant vaccines are most effective when the peptides react with a large responsive part of the tumor-specific T-cell repertoire.Keywords
This publication has 45 references indexed in Scilit:
- Strong CD8+ T-cell responses against tumor-associated antigens prolong the recurrence-free interval after tumor treatment in patients with hepatocellular carcinomaThe Esophagus, 2009
- Self-antigen–specific CD8+ T cell precursor frequency determines the quality of the antitumor immune responseThe Journal of Experimental Medicine, 2009
- Age-dependent tolerance to an endogenous tumor-associated antigenVaccine, 2008
- Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumor vaccinesJCI Insight, 2006
- Use of baculovirus MHC/peptide display libraries to characterize T-cell receptor ligandsImmunological Reviews, 2006
- Diversity and Recognition Efficiency of T Cell Responses to CancerPLoS Medicine, 2004
- A listing of human tumor antigens recognized by T cells: March 2004 updateCancer Immunology, Immunotherapy, 2004
- Mimotopes for Alloreactive and Conventional T Cells in a Peptide–MHC Display LibraryPLoS Biology, 2004
- The Three Es of Cancer ImmunoeditingAnnual Review of Immunology, 2004
- Class I Major Histocompatibility Complex Anchor Substitutions Alter the Conformation of T Cell Receptor ContactsPublished by Elsevier BV ,2001